Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiki Nishimura

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Breast Cancer (Tokyo, Japan)|March 14, 2013
Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTRMakoto Ishitobi, Yasuhiro Okumura, Reiki Nishimura, et al.
Breast Cancer (Tokyo, Japan)|January 8, 2020
Microsatellite instability in Japanese female patients with triple-negative breast cancerKanako Kurata, Makoto Kubo, Masaya Kai, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2020
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETsTakayuki Iwamoto, Tomomi Fujisawa, Tadahiko Shien, et al.
Anticancer Research|July 28, 2004
Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free intervalReiki Nishimura, Takeshi Tominaga, Shoshu Mitsuyama, et al.
Oncotarget|January 21, 2017
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancerHitomi Mori, Makoto Kubo, Rin Yamaguchi, et al.
Cancer|September 14, 2012
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancerHiroji Iwata, Norikazu Masuda, Yasuaki Sagara, et al.
Plos One|November 29, 2022
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapyYuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, et al.
Plos One|December 16, 2016
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerHitomi Mori, Makoto Kubo, Reiki Nishimura, et al.
International Journal of Clinical Oncology|July 27, 2012
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)Kenjiro Aogi, Toshiaki Saeki, Seigo Nakamura, et al.
Breast Cancer Research and Treatment|May 10, 2019
T-bet<sup>+</sup> lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancerHitomi Mori, Makoto Kubo, Masaya Kai, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Breast Cancer (Tokyo, Japan)|March 14, 2013
Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTRMakoto Ishitobi, Yasuhiro Okumura, Reiki Nishimura, et al.
Breast Cancer (Tokyo, Japan)|January 8, 2020
Microsatellite instability in Japanese female patients with triple-negative breast cancerKanako Kurata, Makoto Kubo, Masaya Kai, et al.
Breast Cancer (Tokyo, Japan)|May 13, 2020
The efficacy of sequential second-line endocrine therapies (ETs) in postmenopausal estrogen receptor-positive and HER2-negative metastatic breast cancer patients with lower sensitivity to initial ETsTakayuki Iwamoto, Tomomi Fujisawa, Tadahiko Shien, et al.
Anticancer Research|July 28, 2004
Combination chemotherapy with docetaxel and doxifluridine showed a beneficial outcome in advanced or recurrent breast cancer patients with longer disease-free intervalReiki Nishimura, Takeshi Tominaga, Shoshu Mitsuyama, et al.
Oncotarget|January 21, 2017
The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancerHitomi Mori, Makoto Kubo, Rin Yamaguchi, et al.
Cancer|September 14, 2012
Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancerHiroji Iwata, Norikazu Masuda, Yasuaki Sagara, et al.
Plos One|November 29, 2022
Health-related quality of life and estimation of the minimally important difference in the Functional Assessment of Cancer Therapy-Endocrine Symptom score in postmenopausal ER+/HER2- metastatic breast cancer with low sensitivity to endocrine therapyYuichiro Kikawa, Yasuhiro Hagiwara, Tomomi Fujisawa, et al.
Plos One|December 16, 2016
BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast CancerHitomi Mori, Makoto Kubo, Reiki Nishimura, et al.
International Journal of Clinical Oncology|July 27, 2012
A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)Kenjiro Aogi, Toshiaki Saeki, Seigo Nakamura, et al.
Breast Cancer Research and Treatment|May 10, 2019
T-bet<sup>+</sup> lymphocytes infiltration as an independent better prognostic indicator for triple-negative breast cancerHitomi Mori, Makoto Kubo, Masaya Kai, et al.
Pageof 8